Kaiser Permanente Participating in AbbVie-Sponsored International Clinical Trial Targeting Ovarian Cancer with PARP Inhibitor Called Veliparib

Kaiser Permanente Participating in AbbVie-Sponsored International Clinical Trial Targeting Ovarian Cancer with PARP Inhibitor Called Veliparib

Kaiser Permanente Research radio recently interviewed Dr. Michael A Bookman, an oncologist and investigator with Kaiser, discussing his participation in an international clinical trial sponsored by AbbVie, focusing on a PARP inhibitor called Veliparib to treat ovarian...
AbbVie Will Acquire Allergan in $63 Billion Merger

AbbVie Will Acquire Allergan in $63 Billion Merger

AbbVie and Allergan announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of...

Pin It on Pinterest